Transactivation of erbB2 by short and long isoforms of leptin receptors  by Eisenberg, Avital et al.
FEBS 28334 FEBS Letters 565 (2004) 139–142Transactivation of erbB2 by short and long isoforms of leptin receptorsAvital Eisenberga, Eva Bienera, Madia Charlierb, R.V. Krishnanc, Jean Djianeb,
Brian Hermanc, Arieh Gertlera,*
aFaculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel
bUnite de Neuroendocrinologie Moleculaire de la Prise Alimentaire, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas Cedex, France
cDepartment of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
Received 27 February 2004; revised 28 March 2004; accepted 28 March 2004
First published online 9 April 2004
Edited by Veli-Pekka LehtoAbstract We generated kinase-positive and kinase-negative
erbB2 tagged with YFP and the long form of leptin receptor
(LEPRb) tagged with CFP. Both were as active as their
untagged analogs. Both short and long isoforms of leptin
receptor phosphorylated and thereby activated erbB2 upon leptin
binding and enhanced MAPK activity. Our results unveil a novel
route by which leptin may provoke erbB2’s phosphorylation and
thus enhance its oncogenic potential independently of HER
family ligands or its overexpression. Using FRET technology in
living cells, we found no evidence of complex formation between
erbB2 and prolactin or leptin receptors, indicating that the
transactivation occurs through an indirect interaction.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Identiﬁcation of obesity as a risk factor for breast and
prostate cancer types suggests that adipocyte-derived factors
such as leptin, the level of which is known to increase in obesity,
may play a role in tumor progression [1–4]. Two main isoforms
of leptin receptor, resulting from an alternative splicing, have
been identiﬁed: the short form (LEPRa) and the long form
(LEPRb). Both isoforms have identical extracellular and
transmembrane domains but diﬀer in their intracellular do-
mains [5]. Extensive studies have revealed that only LEPRb is
capable of activating the Jak2/Stat3 pathway [6]. The ubiqui-
tously expressed LEPRa lacks a Stat3 docking site but is still
able to bind and activate Jak2 through box 1 and subsequently
activate the MAPK pathway [7]. Both LEPRb and LEPRa are
expressed and are functional in breast as well as prostate car-
cinoma [1,8]. However, the precise mechanism by which leptin
mediates oncogenic transformation is not yet understood.
ErbB2, a member of the human epidermal growth factor
receptor (HER) family, has been implicated in oncogenic
transformation through its overexpression or the formation of
long-lived signaling heterodimers with other HER family re-
ceptors [9,10]. Exogenous prolactin (PRL), acting through its
receptors and activating Jak2 are capable of erbB2 phosphor-* Corresponding author. Fax: +972-8-936-3208.
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present study, we asked whether LEPR-mediated Jak2 phos-
phorylation can also lead to phosphorylation and subsequent
activation of erbB2. We used ﬂuorescence resonance energy
transfer (FRET) technology in living cells to elucidate the pu-
tative mechanism of PRLR/erbB2 and LEPR/erbB2 cross-talk.2. Materials and methods
2.1. Materials
Expression plasmids encoding cyan and yellow ﬂuorescent proteins
(pECFP-N1, pEYFP-N1, respectively) were from Clontech Inc. (Palo
Alto, CA), the STAT3-responsive pAH32 luciferase-encoding plasmid
was from Merck Research Laboratories (Rahway, NJ). Mouse LE-
PRa, LEPRb and LEPRb-GFP (green ﬂuorescent protein) constructs
were a gift from Dr. C. Bjorbaek and erbB2 constructs were from Dr.
Y. Yarden. Restriction enzymes were from New England-Biolabs
(Saint Quentin en Yvelines, France), monoclonal antibodies (mAbs)
against di-phosphor-MAPK (8159) were from Sigma (St. Louis, MO),
mAb against GFP and fetal bovine serum were from Boehringer
(Manheim, Germany) and mAb anti-phospho-tyrosine (PY20) was
from Transduction Laboratories (Lexington, KY). Anti-serum (Ab
220) against recombinant human leptin-binding domain [12] was pre-
pared in our laboratory. ECL-Western blotting detection reagent was
from Amersham Biosciences (Buckinghamshire, UK). Recombinant
ovine leptin and PRLR-CFP construct were prepared as described
previously [13,14]. OPTIMEM was purchased from Gibco-BRL
(Bethesda, MD), Fugene 6 from Roche Diagnostics Co. (Indianapolis,
IN) and Vectashield mounting medium from Vector Laboratories
(Burlingame, CA). Molecular weight markers for SDS–PAGE, Dul-
becco’s modiﬁed Eagle’s medium (DMEM) and DMEM-HAM F12
medium were obtained from Life Technologies, Inc. (Rockville, MD)
and SDS–PAGE reagents were from Bio-Rad (Hercules, CA). Other
materials were from Sigma.
2.2. Preparation of mLEPRb-CFP, erbB2-YFP and
kinase-negative (KN) erbB2-YFP
LEPRb cDNA inserted into the pEGFP-N1 was digested with AgeI
and BsrGI, isolated from an agarose gel after removal of a 722 bp
insert encoding for GFP, dephosphorylated and ligated into a 722 bp
fragment encoding YFP, prepared by digesting the pEYFP-N1 plas-
mid with the same enzymes, using the Rapid DNA Ligation kit (Roche
Molecular Biochemicals, France). The fused plasmid was prepared by
transforming DH5a Escherichia coli bacteria (Invitrogen, France).
Proper exchange of the GFP fragment with the YFP fragment was
conﬁrmed by the appearance of a new PstI site (position 888), which
exists only in YFP, and not in GFP or CFP. The fragment encoding
erbB2 was isolated from the pcDNA3 vector by digestion with HindIII
and XbaI. Mutagenesis introduced by PCR was performed on the last
700 bp of erbB2 (generated by cleavage of KpnI) to replace the stop
codon by a HindIII site. Following further cleavage the two fragments
were ligated into pEYFP-N1 cleaved by XhoI and HindIII. To create
the KN erbB2-YFP expression vector, KN erbB2 was cleaved withation of European Biochemical Societies.
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and 895 which contains the mutant ATP-binding site. Then, an erbB2-
YFP cleaved with the same enzymes and the mutant fragments were
ligated generating KN erbB2-YFP.
2.3. Total cell-protein extracts, immunoprecipitation and
immunoblotting
HEK 293T cells were cultured as described before [14]. The cells were
transiently transfected with 5 lg KN erbB2-YFP, 4 lg Jak2 and 5 lg
LEPRa, LEPRb or PRLR. Following an overnight incubation in
starvation media, the cells were treated with 400 ng/ml of leptin or PRL
or vehicle for 0–10 min (37 C), washed in cold PBS and lysed [15].
Following 15-min centrifugation at 12 000 g (4 C), 1 mg of total
protein lysate was taken for immunoprecipitation (IP) by incubating
with anti-GFP antibodies in rotation overnight (4 C); 50 ll of protein
A+G agarose was added for 2 h and the immunoprecipitates were
collected by centrifuging for 5 min at 5000 g, washed in lysis buﬀer
(2·), PBS (2·), boiled in reducing sample buﬀer, separated by 10%
SDS–PAGE, immunoblotted with anti-phospho-tyrosine and follow-
ing stripping reprobed with anti GFP.
2.4. Determination of biological activity of LEPRb-CFP
Chinese hamster ovary (CHO) cells, grown in HAM-F12 medium as
described previously [14], were co-transfected with the pCH110, with
STAT3-responsive pAH32 luciferase-encoding plasmid, and with
LEPRb or LEPRb CFP-encoding plasmid, using ExGen 500 (Eu-
romedex, France) according to the manufacturer’s protocol. To test
the biological activity, transfected cells were incubated for 24 h with
diﬀerent concentrations of ovine leptin in a serum free medium of (1/1:
v/v) Dulbecco’s modiﬁed Eagle’s medium (DMEM) and HAM-F12.
The plates were washed with PBS and the enzymatic activity was de-
termined as described previously [16]. The results were expressed as
fold induction, after the luciferase activity was corrected for b-galac-
tosidase activity.
2.5. Determination of MAPK activity
HEK 293T cells were transfected with 650 ng LEPRb or LEPRa, 650
ng Jak2 and either 650 ngor noKNerbB2-YFP.After 36h, the cellswere
washed with PBS and transferred to starvationmedia for 16 h. Then, the
cells were treatedwith 400 ng/ml ovine leptin or vehicle for either 0, 2.5, 5
or 10 min (37 C) and lysed with 150 ll lysis buﬀer [15]. Following
centrifugation for 15 min at 12 000 g (4 C), 75 lg of the lysate’s
protein was separated by SDS–PAGE and transferred to nitrocellulose.
Activated MAPK was detected using anti-di-P MAPK antibodies.
2.6. Fluorescence resonance energy transfer microscopy
FRETmicroscopy is an optical assay to detect protein interactions in
the range of a few nanometers in individual cells [17]. Molecular
proximity between the two ﬂuorophores, LEPRb-CFP (donor) and
erbB2-YFP (acceptor), can be detected by exploiting one of the diﬀerent
manifestations of energy transfer between these ﬂuorescent species [18].
In the present case, we employed the acceptor photobleaching ap-
proach, which involves measuring the changes in donor emission in-
tensity before and after photobleaching (depleting) the acceptor
population [19]. Data acquisition and analysis were performed in a
Zeiss LSM510 laser-scanning microscope as described previously [20].
For transient transfections, HEK 293T cells were grown on coverslips
in a 24-well culture dish (0.7 105 cells/well, 1 ml/well). Each well was
transfected with 100 ng of erbB2-YFP, 150 ng Jak2 and 400 ng LEPRb-
CFP or 50 ng PRLR-CFP using Fugene 6 according to the manufac-
turer’s directions. Forty hours after transfection, the cells were washed
with PBS and serum-free DMEMwas added for 5 h. Then, 400 ng of the
respective hormone (diluted in 0.1%BSA in PBS)was added to eachwell
for diﬀerent periods of incubation.Cellswere thenwashed, ﬁxedwith 4%
paraformaldehyde and mounted using Vectashield mounting medium.Fig. 1. Expression of erbB2-YFP (upper) or KN erbB2-YFP (lower).
HEK 293T cells were transfected with the respective constructs and
grown for 48 h. Cells were then ﬁxed and analyzed by confocal mi-
croscope. (A) Confocal images; (B) the corresponding overlayed
transmitted-light images. For details see text.3. Results
3.1. Expression of YFP-tagged erbB2 and CFP-tagged short
and long leptin receptors
Expression of YFP-tagged erbB2 and KN erbB2 in HEK
293T cells was visualized by ﬂuorescence microscopy (Figs. 1and 4A); the localization of the expressed fusion protein is
conﬁned to cell membranes. Expression of CFP-tagged LEPRa
and LEPRb in transiently transfected HEK 293T cells was
veriﬁed by IP with Ab 220, followed by immunoblotting with
anti-GFP Ab, and the expected bands were revealed with the
respective moleculer masses of 205 and 125 kDa (not shown).
The presence of LEPRb and LEPRa was also validated by
binding of 125I ovine leptin, yielding a respective speciﬁc
binding of 55 7 and 86 5 fmol (mean S.E.M., n ¼ 3) 125I
ovine leptin/well containing an average of 106 cells.
3.2. Biological activity of CFP-tagged and untagged short
and long leptin receptors
The biological activities of LEPRb-CFP and non-tagged
LEPRb were tested in CHO cells. Leptin-induced luciferase
activity (50 and 200 ng/ml, respectively) in cells transfected
with LEPRb-CFP (7.5 1.1- and 15.6 2.0-fold induction)
was similar to cells transfected with untagged LEPRb
(7.0 1.2- and 11.6 2.3-fold induction). Both tagged (not
shown) and untagged LEPRa and LEPRb (Figs. 2 and 3) were
also capable of phosphorylating erbB2 and activating MAPK.
3.3. Leptin or PRL-receptor-enhanced phosphorylation
of KN erbB2-YFP
In cells co-transfected with DNA encoding LEPRa or
LEPRb, Jak2 and KN erbB2-YFP, 5 min exposure to 25 nM
leptin resulted in signiﬁcant and speciﬁc phosphorylation of
the latter. The phosphorylation could already be seen in the
total cell lysate (TCL) and was veriﬁed by IP with a-GFP
(Fig. 2A and B). No such phosphorylation was seen in cells not
exposed to leptin or in cells transfected with only Jak2 and KN
erbB2-YFP (not shown). Similar results were obtained in cells
Fig. 4. FRET microscopy. (A) Multitrack imaging of HEK 293T cells
transfected with LEPRb-CFP (upper) or PRLR-CFP (lower) along
with erbB2-YFP. (B) Time-dependent leptin- or PRL-induced FRET
signal in cells transfected with LEPRb-CFP/erbB2-YFP (j) or PRLR-
CFP/erbB2-YFP (). For details see text.
Fig. 2. Leptin- or prolactin-enhanced phosphorylation of KN erbB2-
YFP. HEK 293T cells transfected with KN erbB2-YFP, Jak2 and ei-
ther LEPRb (A) or LEPRa (B) were treated with 400 ng/ml leptin as
indicated. Lysates were subjected to IP using anti-GFP antibodies or
no antibody as a control (*), separated by SDS–PAGE along with
samples from the TCL and immunoblotted using anti-phospho-tyro-
sine (PY) and reprobed with anti-GFP. (C) Immunoprecipitates from
cells transfected with KN erbB2-YFP, Jak2 and PRLR, which were
treated with 400 ng/ml PRL. Other details as in (A) or (B).
Fig. 3. MAPK activation in cells transfected with Jak2, LEPRa or
LEPRb and KN erbB2-YFP. HEK 293T cells were transfected with
either LEPRb (A) or LEPRa (B), Jak2 and either with or without KN-
erbB2-YFP as indicated. Following overnight starvation cells were
treated with 400 ng/ml leptin for up to 10 min. The lysates were sep-
arated by SDS–PAGE and immunoblotted with anti-di-phosphory-
lated MAPK antibodies. (C) Cells transfected with PRLR, Jak2 and
increasing amounts of KN-erbB2-YFP were starved, treated with 400
or 700 ng/ml prolactin for 5 min and checked for MAPK activation as
above.
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PRL (Fig. 2C), conﬁrming others’ results [11], and showing
that tagging the KN erbB2 with YFP does not interfere with its
ability to be phosphorylated.
3.4. MAPK activation in cells transfected with Jak2, LEPRa
or LEPRb and KN-erbB2-YFP
Exposure to leptin in HEK 293T cells transfected with either
LEPRa or LEPRb resulted in time-dependent activation of
MAPK, the eﬀect being stronger in the latter. The results
cannot be attributed to diﬀerential expression of MAPK, as
the amount of total MAPK was similar in cells transfected
with LEPRa and LEPRb (not shown). However, when the
cells were co-transfected with KN erbB2-YFP, MAPK acti-
vation was both stronger and faster (Fig. 3A and B), in con-
trast to the relatively weaker response in cells transfected with
LEPRa in the absence of KN-erbB2-YFP. Similar results wereobtained in cells transfected with PRLR and KN erbB2-YFP
(Fig. 3C), indicating that tagging of KN erbB2 with YFP does
not aﬀect its ability to activate MAPK.
3.5. FRET in HEK 293T cells co-transfected with KN
erbB2-YFP and LEPRb-CFP or PRLR-CFP
In order to elucidate the possible mechanism of KN erbB2-
YFP activation by leptin or PRL receptors tagged with CFP,
we employed acceptor photobleaching FRET microscopy to
detect an interaction between the receptor types. To ensure the
proper experimental conditions, only cells expressing similar
amounts of expression of CFP- and YFP-tagged proteins were
chosen (Fig. 4A). In each case, two independent experiments
were carried out in cells exposed to the respective hormone for
up to 30 min. The results shown in Fig. 4B, clearly indicate
that there is no signiﬁcant FRET signal and hence, there is no
interaction between the receptors during the tested period.
Minor variations in FRET eﬃciency reﬂect experimental error
only. In the case of co-transfection of KN erbB2-YFP and
PRLR-CFP, a decrease in FRET signal was observed after 30
142 A. Eisenberg et al. / FEBS Letters 565 (2004) 139–142min of exposure to the hormone. It should be noted that a
signiﬁcant FRET was measured using similar technique in a
diﬀerent system [14], as well as by measuring LEPRb-YFP and
LEPPRb-CFP interaction (unpublished data) and thus ex-
cluding the possibility of technical failure. An attempt to co-
immunoprecipitate LEPRb and erbB2-YFP using anti GFP
Abs was also unsuccessful. Though a band of 205 kDa cor-
responding to LEPRb was observed in the supernatant after
IP, no such band was seen in the immunoprecipitated erbB2-
YFP using commercially available anti-LEPR Ab.4. Discussion
We demonstrate that KN erbB2-YFP is as active as its un-
tagged analog and show transactivation of KN erbB2-YFP by
both LEPRa and LEPRb, since both LEPRs phosphorylated
KN erbB2 and subsequently promoted MAPK activation.
Despite the fact that LEPRa has a lesser ability to activate
MAPK (unpublished data), in our case its capacity to enhance
phosphorylation of KN erbB2 and activation of MAPK
through transactivation of KN erbB2 was stronger than that
of LEPRb. Though it could be partially attributed to its higher
expression (see reblot with a-GFP in Fig. 3), this ﬁnding may
be of physiological or pathological signiﬁcance as LEPRa is
more abundant in peripheral tissues. Our present results show
that not only PRL, but also leptin and perhaps other cytokines
such as IL6 [21], oncostatin M [22] and tumor necrosis factor
[23], may transactivate erbB2; as such they may unveil a novel
route by which cytokines promote erbB2 phosphorylation and
enhance its oncogenic potential independently of HER family
ligands or its overexpression. The case of leptin is of particular
interest as both the hormone and obesity have been linked to
increased risk of carcinogenesis [1–4,8]. Therefore, a hypo-
thetical situation, in which the same cell overexpresses erbB2
and leptin or PRL receptors along with high circulating levels
of those hormones, makes it potentially more vulnerable to
oncogenic transformation and tumor promotion.
In the present work, we also tried to elucidate the molecular
mechanism underlying the putative cross-talk between the
LEPRs or PRLR and erbB2 by measuring their appearance
under FRET microscopy. As no hormone-dependent FRET
signal was observed, two alternative interpretations of our
results can be suggested: (a) PRLR/LEPR and erbB2 do not
interact and Jak2, activated by PRLR or LEPR translocates to
activate erbB2; or (b) PRLR/LEPR and erbB2 do form a
complex through binding to Jak2 but the cytosolic domains of
these receptors are not close enough to be observed by FRET.
The present data do not enable a determination of which in-
terpretation is correct. However, further experiments involving
FP-tagged Jak2 or anisotropy experiments to be executed in
the near future will likely resolve this question.Acknowledgements: This work was supported by the Binational USA –
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